{
    "id": 4280,
    "name": "nodular basal cell carcinoma",
    "source": "DOID",
    "definition": "A basal cell carcinoma characterized by elevated, pearl shaped nodules with telengactisae on the surface and periphery. [url:https\\://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573444/]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "4296"
    ],
    "termId": "DOID:4280",
    "evidence": [
        {
            "id": 3853,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Dz13 demonstrated safety, reduced tumor c-Jun expression, and showed some preliminary efficacy in patients with nodular basal cell carcinoma (PMID: 23660123).",
            "molecularProfile": {
                "id": 16528,
                "profileName": "JUN positive"
            },
            "therapy": {
                "id": 3371,
                "therapyName": "Dz13",
                "synonyms": null
            },
            "indication": {
                "id": 4280,
                "name": "nodular basal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4239,
                    "pubMedId": 23660123,
                    "title": "Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a phase 1 first-in-human trial (DISCOVER).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23660123"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        
    ]
}